Hamza Farooq is the Co-Founder and Chief Technology Officer of BioBox Analytics, where he leads the development of graph-powered AI systems designed to accelerate drug discovery. His work centers on applying knowledge graphs, GraphRAG, and agentic architectures to transform complex biomedical data into reliable, interpretable tools for scientific reasoning.

With a background in bioinformatics and production-scale AI systems, Hamza brings a practitioner’s perspective to building AI for biology—grounded in real data, real users, and real constraints. He regularly works with pharma and biotech teams to move graph-based AI beyond demos and into production, enabling scientists to explore evidence, connect concepts, and generate insights at scale.

Hamza Farooq is the Co-Founder and Chief Technology Officer of BioBox Analytics, where he leads the development of graph-powered AI systems designed to accelerate drug discovery. His work centers on applying knowledge graphs, GraphRAG, and agentic ar... Show more

Bruce R. Krawisz, M.D.
Born: 1952 in Chicago, Illinois
Undergraduate: Macalester College, St. Paul, MN, biology/chemistry, BA 1974.
Graduate: Mayo Medical School, Rochester, MN, medicine, MD, 1978.
Postdoctoral: Mayo Graduate School of Medicine and Washington University in St. Louis, 1978 - 1984, Board Certifications in Anatomic Pathology (1982) and Molecular Genetic Pathology (2001).
Marshfield Clinic Research Institute, Emeritus Researcher, 2017 – present
Prevention Genetics, Clinical Laboratory Director, 2006 – 2016
Marshfield Clinic, Pathologist, 1989 – 2016
University of Vermont School of Medicine, Assistant Professor of Pathology, 1984 - 1989

Bruce R. Krawisz, M.D. Born: 1952 in Chicago, Illinois Undergraduate: Macalester College, St. Paul, MN, biology/chemistry, BA 1974. Graduate: Mayo Medical School, Rochester, MN, medicine, MD, 1978. Postdoctoral: Mayo Graduate School of Medicine a... Show more

Dr. Halappanavar is a chief data scientist at PNNL, where he serves as the group lead of the Data Science and Machine Intelligence group. He also holds a joint appointment as adjunct faculty in computer science at Washington State University in Pullman. His research has spanned multiple technical foci and includes combinatorial scientific computing, parallel graph algorithms, artificial intelligence and machine learning, and the application of graph theory and game theory to solve problems in application domains, such as scientific computing, power grids, cybersecurity, and life sciences. He has authored over 170 technical publications for peer-reviewed journals, conferences, and workshops.

Dr. Halappanavar is a chief data scientist at PNNL, where he serves as the group lead of the Data Science and Machine Intelligence group. He also holds a joint appointment as adjunct faculty in computer science at Washington State University in Pullm... Show more

Carol Tinga is a Postdoctoral Scholar at the Ontario Veterinary College (OVC), University of Guelph, Canada. She earned her PhD at OVC, focusing on owner-companion rabbit relationships and rabbit welfare. Her research examined the use of human-animal relationship scales for rabbit owners, risk factors for relinquishment and abandonment, and recent trends in domestic rabbit intake and management at shelters and rescues in Canada and the USA. Currently, Carol is preparing four open-access publications based on her thesis, presenting findings at conferences, and supporting organizations that care for rabbits. Additional upcoming papers will address access to veterinary care, challenges of rabbit ownership, owners’ favourite rabbit behaviours and their significance, and the validation of a third relationship scale. Vespa, a remarkable lop-eared rabbit, inspired her PhD. Before her doctoral studies, Carol completed an MSc in epidemiology, exploring how veterinary students and recent graduates perceive their technical and professional skills. She now shares her home with Ellie and Coco, a bonded pair of free-range rabbits affectionately known as “the hooligans,” adopted after they were abandoned outdoors.

Carol Tinga is a Postdoctoral Scholar at the Ontario Veterinary College (OVC), University of Guelph, Canada. She earned her PhD at OVC, focusing on owner-companion rabbit relationships and rabbit welfare. Her research examined the use of human-animal... Show more

1999-2004
Faculty of Science, Charles University, Biology, Mgr. degree
2004-2010
Faculty of Science, Charles University, Molecular Biology, Ph.D. degree
Publications:
https://pubmed.ncbi.nlm.nih.gov/?term=valis+k+NOT+St.+Anne%27s+University+Hospital+Brno&sort=pubdate

1999-2004 Faculty of Science, Charles University, Biology, Mgr. degree 2004-2010 Faculty of Science, Charles University, Molecular Biology, Ph.D. degree Publications: https://pubmed.ncbi.nlm.nih.gov/?term=valis+k+NOT+St.+Anne%27s+University+Ho... Show more

I’m a 3x founder working at the intersection of quantum computing, AI, and tech media. Over the past 15 years, I’ve helped build and advise deep tech startups across next-gen computing and hardware. Today, I reach over 160K people across social platforms, and was recently named one of the Top 40 Silicon Valley Influencers.

I’ve spoken at events like SXSW, RSA, and the Quantum Innovation Summit in Dubai, and have been invited by teams at Google DeepMind and NVIDIA to cover their flagship launches. My work draws an audience of engineers, founders, and investors, who want a front-row seat to what’s next in tech, minus the buzzwords. In addition to deep subject-matter expertise, I bring massive online exposure and proven storytelling to drive attention and engagement.

I’m a 3x founder working at the intersection of quantum computing, AI, and tech media. Over the past 15 years, I’ve helped build and advise deep tech startups across next-gen computing and hardware. Today, I reach over 160K people across social platf... Show more

Jennifer White, B.Sc., M.I.D.S.T., ACAAB (ABS), combines professional education with lived experience as an Associate Certified Applied Animal Behaviorist (ACAAB) through the Animal Behavior Society. Her passion for understanding animal behaviour began in childhood and grew through her work with homeless animals and her own rescue Doberman, Cocoa, whose behavioural challenges inspired her to pursue advanced training.

Jennifer holds a Master of Interdisciplinary Studies in Animal Behaviour and Welfare from the University of New Brunswick and a Certificate in Applied Animal Behavior from the University of Washington. Through her consulting practice, Thriving Animal Behaviour Solutions, she works with pet owners, shelters, and animal welfare organizations to develop practical, welfare-focused behaviour support systems that improve outcomes for both animals and the people who care for them.

Jennifer serves as Vice President of the Fredericton SPCA Board of Directors, where she supports initiatives that advance animal welfare in her community. She is passionate about education and helping organizations and animal caregivers build stronger, more compassionate relationships with animals through evidence-based behaviour support.

Jennifer White, B.Sc., M.I.D.S.T., ACAAB (ABS), combines professional education with lived experience as an Associate Certified Applied Animal Behaviorist (ACAAB) through the Animal Behavior Society. Her passion for understanding animal behaviour beg... Show more

Dr. Richard L. Watkins is a scientist, strategist, and advocate working at the intersection of research, policy, and society. He is the Founder, Chairman, and CEO of The Science Policy Action Network, Inc. (SPAN), where he is responsible for setting the organization’s overall direction and service strategy. He leads the development of SPAN’s consulting offerings and operational infrastructure, with a focus on impact across education, innovation, and public health.

Dr. Watkins holds a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill and a B.S. in Psychology from Fayetteville State University. His scientific background informs a systems-level approach to policy advising and program design, particularly in areas such as school safety, mental health, and science-based governance.

A dynamic communicator and bridge-builder, Dr. Watkins also hosts The Richard Watkins Podcast, a platform for thought leaders across disciplines. His work continues to shape public conversations and institutional strategies through science, equity, and community engagement.

Dr. Richard L. Watkins is a scientist, strategist, and advocate working at the intersection of research, policy, and society. He is the Founder, Chairman, and CEO of The Science Policy Action Network, Inc. (SPAN), where he is responsible for setting ... Show more

Transformational R&D Leader delivering validated ROI through AI-enabled digital modernization, regulatory systems innovation, regulatory strategy development, and scaled global operating models. Proven expertise in architecting enterprise-wide frameworks adopted globally across regulatory affairs, CMC, clinical development, quality, and safety. Recognized as a thought leader on regulatory strategy and technology. Track record translating business strategy into operational capabilities that accelerate product approvals and optimize R&D portfolio performance

Transformational R&D Leader delivering validated ROI through AI-enabled digital modernization, regulatory systems innovation, regulatory strategy development, and scaled global operating models. Proven expertise in architecting enterprise-wide framew... Show more

Shovan Saha serves as Associate Director of Clinical Data Management at Daiichi Sankyo with over 18 years of comprehensive clinical trial experience spanning the complete lifecycle from study startup through database lock activities. Specializing in oncology for 14+ years, he has served as Lead Data Manager and Program Clinical Data Manager for five FDA-submitted and approved cancer treatments across breast cancer, hepatocellular carcinoma, melanoma, pancreatic neuroendocrine tumors, and tuberous sclerosis complex. His expertise encompasses Phase I-IV studies with particular strength in Phase III pivotal trials that achieved regulatory approval. Shovan demonstrates technical proficiency across multiple Clinical Data Management Systems including Oracle Clinical, Oracle RDC, Inform, Rave, Clintrail, and PHOSCO, complemented by expertise in data visualization platforms such as Spotfire, ICRS, and J-Review.
With 12+ years successfully managing international CRO relationships, he currently leads multidisciplinary teams of 4-6 staff while providing strategic oversight for complex global initiatives including electronic SAE reporting system implementation and safety database integration. He previously held the Certified Clinical Data Manager (CCDM) designation from SCDM and earned his Master of Science in Biotechnology from Bangalore University. Currently, Shovan is advancing multiple antibody-drug conjugate (ADC) treatment projects across non-small cell lung, gastric, prostate, and breast cancers toward regulatory approval, maintaining the highest standards of data integrity and regulatory compliance throughout the drug development process.

Shovan Saha serves as Associate Director of Clinical Data Management at Daiichi Sankyo with over 18 years of comprehensive clinical trial experience spanning the complete lifecycle from study startup through database lock activities. Specializing in ... Show more

Biomedical engineer with more than 15 years of expertise.

Biomedical engineer with more than 15 years of expertise. Show more

Rudi Schmidt serves as CEO at the Amanahyat Institute in Abu Dhabi (AIAD) and as Managing Partner at Seven Shams (7S). AIAD evaluates biomedical organizations and companies, their assets and business models for family offices, sovereign wealth funds, and Private Equity in the context of financing rounds, M&A and due diligence reviews. 7S oversees GCC/UAE market entries in the regulated environments of life sciences, biotech, AI, and digital platforms.

Before AIAD, Rudi served as COO at the Institute for Healthier Living Abu Dhabi and as CEO at !mmunetrue, a company that analyzes immunological patterns across diseases and treatments.

Rudi Schmidt also spent 15 years at Asklepios Hospitals, the 2nd largest hospital chain in Europe, the last 7 years as EVP Precision Medicine, and as CEO of several Asklepios affiliates, including a metagenome company and a provider of Real-World Data in precision medicine for commercial R&D.

In previous leadership positions, Rudi was responsible for Corporate Communications and Investor Relations at Europe's largest listed IT system house (Bechtle AG) and at debitel AG, a joint venture between DaimlerChrysler, Metro and EP, which was later acquired by Swisscom AG.

Rudi Schmidt serves as CEO at the Amanahyat Institute in Abu Dhabi (AIAD) and as Managing Partner at Seven Shams (7S). AIAD evaluates biomedical organizations and companies, their assets and business models for family offices, sovereign wealth funds,... Show more

The Climate Adventurer
Bernice Notenboom is one of the world's most prominent explorers focusing on the climate crisis. She translates complex scientific data from the Earth's most remote regions into compelling stories for a global audience. She splits her time between the Netherlands and the mountains of Fernie, British Columbia. Bernice Notenboom's latest work and documentaries focus heavily on the intersection of extreme survival and climate action. Here is the summary of her newest book and where to find her films:

New Book: Survival Mind (2025)
Released in October 2025, Survival Mind moves beyond technical survival gear to explore the "inner equipment" of the human brain.

The Core Question: Why do some people survive extreme life-and-death situations while others do not? Is it instinct, mental strength, or pure luck?

Scientific Insight: Notenboom combines hair-raising personal stories from her expeditions (including a near-fatal accident in Siberia) with neuroscience to explain how the brain makes decisions under intense pressure. Key Takeaway: The book is designed to help readers build resilience and "mental vitality" for everyday life and the growing challenges of the climate crisis. It has been praised by physiologists and critics for its clear, personal style that makes you feel like an expedition member yourself.

The Climate Adventurer Bernice Notenboom is one of the world's most prominent explorers focusing on the climate crisis. She translates complex scientific data from the Earth's most remote regions into compelling stories for a global audience. She sp... Show more

Leading Life science related projects across multiple Crossfunctional area of industry

Leading Life science related projects across multiple Crossfunctional area of industry Show more

Mark Bouzyk is a biotechnology executive and scientist with a career built across academic research, pharmaceutical development, and biotechnology innovation. His work has consistently focused on genetics, genomics, precision medicine, pharmacogenomics, oncology, and digital health. With formal training in biochemistry and human molecular genetics, he developed a structured and careful approach to scientific inquiry. Throughout his career, he has remained grounded in the idea that science should be practical, ethical, and beneficial to patients, researchers, and healthcare systems, rather than driven solely by recognition or complexity.

Mark began his professional path in academic research, where he worked as a research officer studying the molecular and genetic mechanisms underlying viral drug resistance. His early responsibilities involved examining how genetic variation influences biological structure, function, and treatment response. He later supported cancer research efforts by applying foundational molecular biology techniques to studies of cellular signaling and growth regulation. During this time, he also contributed to large collaborative genome-mapping projects, gaining experience in coordinated research, data-intensive analysis, and cross-institutional scientific teamwork.

Mark Bouzyk later moved into the pharmaceutical industry, where he held senior scientific roles focused on genetic technologies and laboratory science. He established and managed critical research infrastructure, supported innovation in genetics, and earned recognition for consistent scientific contributions. As his scope expanded, he led integrated genetics organizations, developed high-throughput genotyping operations, and implemented global systems for genetic sample and data management. He oversaw teams, budgets, and quality processes while supporting pharmacogenetic and disease-association studies that informed safer, more reliable drug development.

Bouzyk advanced into leadership roles with broader strategic responsibility, overseeing discovery projects across international research locations. He guided genetics programs from planning through execution, ensuring alignment with organizational priorities and research objectives. By working closely with senior leadership, he helped identify operational limitations, improve resource use, and strengthen coordination across distributed teams. His leadership style emphasized clarity, collaboration, and measured progress, allowing complex research portfolios to move forward efficiently while maintaining consistency and scientific integrity.

Mark Bouzyk later returned to an academic medical environment as a faculty member, where he directed multiple core laboratories and genomics centers supporting translational research. He built service platforms that connected experimental genetics with clinical studies, enabling cross-disciplinary collaboration. Alongside this work, he demonstrated entrepreneurial leadership by co-founding biotechnology and digital health companies focused on genomics, biomarker development, and clinical workflow improvement. Outside professional life, he values family, creative pursuits, physical activity, and long-term support for animal welfare efforts rooted in compassion and responsibility.

Mark Bouzyk is a biotechnology executive and scientist with a career built across academic research, pharmaceutical development, and biotechnology innovation. His work has consistently focused on genetics, genomics, precision medicine, pharmacogenomi... Show more

Information Technology, Life Sciences

Information Technology, Life Sciences Show more

Piero Palacios
Biologist | Data Scientist | Bioinformatic Scientist

Hello! I’m Piero, a biologist from Peru with a strong foundation in biotechnology. My passion for data analysis and bioinformatics has led me to pursue specializations from Harvard University and MIT. In my free time, I enjoy creating reproducible and interactive reports using Quarto.

My bioinformatics expertise spans various domains, including RNA-Seq, Methyl-Seq, WGBS-Seq, Illumina Methylation Array, and multi-omics analyses. Additionally, I have extensive experience in machine learning (e.g., OLS, ridge and lasso regression, SVM, kernels, collaborative filtering, network analysis, high-dimensional reduction) and deep learning models (e.g., feed-forward neural networks, recurrent neural networks, convolutional neural networks, graph neural networks, transformers).

I'm excited to connect, share ideas, and explore innovative applications of Shiny at this conference!

Piero Palacios Biologist | Data Scientist | Bioinformatic Scientist Hello! I’m Piero, a biologist from Peru with a strong foundation in biotechnology. My passion for data analysis and bioinformatics has led me to pursue specializations from Harva... Show more

Me recibí el año pasado de la Licenciatura en Física en la Universidad Nacional de La Plata. Allí soy ayudante en materias de primer año de la carrera, y trato de transmitir la importancia de la programación para hacer investigación en física. Ahora estoy realizando un doctorado en Física en el Instituto de Física de Líquidos y Sistemas Biológicos.

Me recibí el año pasado de la Licenciatura en Física en la Universidad Nacional de La Plata. Allí soy ayudante en materias de primer año de la carrera, y trato de transmitir la importancia de la programación para hacer investigación en física. Ahora ... Show more

I am a molecular biologist/computational biologist who stumbled upon a data analyst role. I wear three hats at work: I teach data science, genomics and evolution to undergraduates; I study patterns of genetic variation in small mammals to learn about their evolution and demography; I analyse and report on students' educational outcomes and factors that contribute to differential attainment of various groups of students across the entire institution. I also like to cycle.

I am a molecular biologist/computational biologist who stumbled upon a data analyst role. I wear three hats at work: I teach data science, genomics and evolution to undergraduates; I study patterns of genetic variation in small mammals to learn about... Show more

I studied geography in my bachelor's degree. In my master's, I study geodesy and geoinformation science. Since 2022, I have been working in geostatistics at the Freie Universität Berlin.

I studied geography in my bachelor's degree. In my master's, I study geodesy and geoinformation science. Since 2022, I have been working in geostatistics at the Freie Universität Berlin. Show more

I am a distinguished data science leader. I currently serve as Senior Director at Axtria Inc., where I lead the company’s decision science business across the Midwest and West Coast. I manage a five million dollar portfolio and guide a team of high performing data scientists who build advanced analytics and AI solutions for global biopharmaceutical clients. My work focuses on transforming commercial decision making, improving patient outcomes, and institutionalizing data driven strategies across large enterprises.

At Axtria, I have led several pioneering analytics initiatives. I developed a patient journey map for a cardiomyopathy therapy by analyzing more than fifty thousand EMR and claims records. This work uncovered diagnostic delays, identified adherence gaps, and enabled targeted interventions that improved therapy initiation by fifteen percent and adherence by twenty percent. For a leading HIV drug, I designed and implemented advanced multi touch attribution models that quantified the influence of interactions across HCPs, pharmacies, and digital channels, enabling more precise promotional decision making. I also built a comprehensive omnichannel orchestration strategy for a cancer drug, aligning marketing, medical, and compliance functions to deliver synchronized and compliant outreach. In addition, my work in econometric modeling for a CNS drug delivered a ten percent uplift in total sales through optimized budget allocation and a clear understanding of channel effectiveness.

My thought leadership has been featured at leading international conferences. I have delivered keynote addresses at the IEEE International Conference on Communication, Computer Sciences and Engineering and have been invited to speak at the IEEE International Conference on Contemporary Computing and Communications. My talk titled Leveraging Data Science for Transformative Healthcare Outcomes received significant engagement for its practical approach to integrating predictive analytics into healthcare ecosystem design. I have also contributed multiple scholarly works to international journals and IEEE venues, including Leveraging Statistical Programming for Adaptive Clinical Trial Designs at ICCSCM, Innovations in Multi Touch Attribution Models at the IEEE ESCI Conference, and Revolutionizing Customer Experience Through NLP and Sentiment Analysis Strategies at the IEEE CICTN Conference.

Across my career, I have been driven by a consistent mission to unlock measurable value through data. I have mentored and developed high performing analytics teams, scaled global capabilities, and advised senior leaders across healthcare, life sciences, insurance, retail, and manufacturing. My work stands at the intersection of strategy, analytics, and technology, ensuring that organizations can translate complex data into decisions that elevate outcomes for patients, customers, and businesses.

I have a proven track record of building, scaling, and elevating high-performing analytics and data science teams across multiple geographies. Throughout my leadership roles at Axtria, TheMathCompany, and Mu Sigma, I have hired and developed dozens of data scientists, analysts, and decision science professionals—creating strong talent pipelines, capability-building frameworks, and onboarding programs that accelerate both readiness and long-term success. I am deeply committed to coaching and mentoring, providing structured career development, real-time feedback, and hands-on guidance that helps my teams grow into strategic, client-facing leaders. My leadership style blends technical depth with people-focused mentorship, enabling me to build teams known for analytical rigor, commercial impact, and exceptional professional growth.

I continue to anchor my work in innovation, academic rigor, and a commitment to improving healthcare systems through the power of data science and artificial intelligence. My journey reflects a belief that the right analytical models, when combined with the right strategic intent, can meaningfully improve lives at scale.

I am a distinguished data science leader. I currently serve as Senior Director at Axtria Inc., where I lead the company’s decision science business across the Midwest and West Coast. I manage a five million dollar portfolio and guide a team of high p... Show more

[Dr. Alexander Jarasch](https://www.linkedin.com/in/alexanderjarasch/) is Neo4j’s Global Head of Pharma & Life Sciences at Neo4j, the graph database and analytics leader. He specializes in AI, ML, and data engineering within this domain. He also works on combining GenAI with knowledge graphs for target identification, competitive intelligence and in supply chain. With a bioinformatics background, his career spans chemistry, biotech, pharma, and IT. Dr. Jarasch has received numerous awards for innovative analytics techniques such as knowledge graphs to combat diseases such as diabetes. Prior to Neo4j, Dr Jarasch was the Head of Data and Knowledge Management at the German Center for Diabetes Research (DZD), following prior roles at Roche Diagnostics, the Max Planck Institute for Biochemistry, and other organizations.  He speaks frequently at major healthcare conferences and his published articles can be found in peer-review journals such as SCIENCE, PNAS, Nature Structural & Molecular Biology and Bioinformatics.

[Dr. Alexander Jarasch](https://www.linkedin.com/in/alexanderjarasch/) is Neo4j’s Global Head of Pharma & Life Sciences at Neo4j, the graph database and analytics leader. He specializes in AI, ML, and data engineering within this domain. He also work... Show more

Hello! I'm a research assistant in the Human Analysis and Biometrics group at Oak Ridge National Laboratory. I've been working there since 2021, shortly after having graduated from the University of Michigan with a BS in Physics and German. My focus so far has been biometric dataset collection and curation, utilizing a range of commercial sensors, and developing custom camera systems and software. I am a major contributor to the collection and curation efforts that produced the BRIAR datasets. I am currently working on imaging, biometric signals, and time series classification projects.

Hello! I'm a research assistant in the Human Analysis and Biometrics group at Oak Ridge National Laboratory. I've been working there since 2021, shortly after having graduated from the University of Michigan with a BS in Physics and German. My focus ... Show more

As a system biologist, I provide consultancy and architecture for organisation and information systems based on natural principles

As a system biologist, I provide consultancy and architecture for organisation and information systems based on natural principles Show more

M. Castro Gbêmêmali Hounmenou holds a PhD in Statistics-Probability and is a post-doctoral researcher in Biostatistics and Artificial Intelligence at the Research and Training Center in Infectiology of Guinea (CERFIG), Gamal Nasser University of Conakry, Guinea. Previously, he was a Lecturer-Researcher at the Laboratory of Biometrics and Forestry Estimations at the University of Abomey-Calavi, Benin. He actively participates in various scientific communities, contributing to fields such as biostatistics, applied statistics, machine learning, artificial intelligence, climate change, agriculture, environment, and public health. He has received several awards, including the best poster award for his doctoral thesis work at the Doctoral School of Excellence Centers of Benin of the World Bank in 2021, and was nominated in 2024 among 'World Top Scientists' in the 'Best Research Article Award' category in Biostatistics. Recently, he has been appointed as a Lecturer-Researcher in Artificial Intelligence at the University of Labé. Contact: +22995306612/+224627812787, castrohounmenou@gmail.com

M. Castro Gbêmêmali Hounmenou holds a PhD in Statistics-Probability and is a post-doctoral researcher in Biostatistics and Artificial Intelligence at the Research and Training Center in Infectiology of Guinea (CERFIG), Gamal Nasser University of Cona... Show more

Biologist and Statistician, with a phD in Ecology and specialization in Data Science. Working as data analysis in public service for the past seven years.

Biologist and Statistician, with a phD in Ecology and specialization in Data Science. Working as data analysis in public service for the past seven years. Show more

I have been using Rust full-time since 2017 to design software that makes predictions for the Large Hadron Collider at CERN. During my PhD and 5-year postdoc at ETH, I designed computer algebra programs that can handle massive computations involving expressions with millions of terms that can easily take up a terabyte of memory. This specialized software is based on programs from the 1990s, which are hard to use, and very hard to maintain.

At the end of 2022, I decided to design a new computer algebra package from scratch in Rust that is both easy to use and is blazing fast: Symbolica.

I have been using Rust full-time since 2017 to design software that makes predictions for the Large Hadron Collider at CERN. During my PhD and 5-year postdoc at ETH, I designed computer algebra programs that can handle massive computations involving ... Show more

Angeliki Cooney has been a transformative figure in the life sciences industry for over two decades, based in Wynantskill, NY. Her career is marked by a commitment to improving the development and accessibility of innovative therapies for chronic conditions, rare diseases, and cancer.

Angeliki's professional endeavors have primarily focused on strategic consulting for biopharmaceutical companies, specializing in digital transformation, omnichannel customer engagement, and optimizing commercial strategies. She has been instrumental in developing several innovative software-as-a-service (SaaS) products for the life sciences sector, which have earned her three patents, underscoring her role as a pioneer in the field.

In her recent role as Senior Vice President of Life Sciences at Avenga, Angeliki spearheaded the company's U.S. expansion strategies. Avenga is a global digital consulting and engineering leader, partnering with some of the biggest names in pharmaceuticals and biotechnology. Under her leadership, the company expanded its clientele and solidified its presence in the competitive U.S. market.

Before Avenga, Angeliki served as Principal Group Lead of Commercial Excellence at Axtria, overseeing a diverse portfolio of clients across the U.S. and Europe. Her strategic initiatives and innovative engagement models contributed significantly to the company's rapid growth.

Her previous roles included Senior Director of Life Sciences Consulting at Gartner, where she bridged the gap between strategic business needs and I.T. operational solutions for life sciences clients. Angeliki also held impactful positions at New York Life Insurance, IMS Health, and Z.S. Associates, where she led digital and analytics transformations to enhance healthcare outcomes.

Angeliki's passion for pharmaceuticals was ignited during a childhood internship at her godfather's pharmacy, an experience that shaped her future career path. She pursued higher education with an MBA from Harvard Business School and an M.S. in Chemical Engineering from the University of Patra, Greece.

Beyond her professional life, she is passionate about skiing, a hobby she shares with her family, inspired by her son's love for the sport. She also strongly connects to her Greek heritage, actively supporting humanitarian efforts during crises and frequently visiting Greece to stay connected with her roots and family. Angeliki Cooney's career exemplifies her dedication to driving healthcare innovation and strategic development in the life sciences industry.

Angeliki Cooney has been a transformative figure in the life sciences industry for over two decades, based in Wynantskill, NY. Her career is marked by a commitment to improving the development and accessibility of innovative therapies for chronic con... Show more

Imagining Tomorrow's Science, a Methodology for Radical Imagination in Science and Technology from today.
Radical Imagination to focus on encouraging highly creative, unconventional, or groundbreaking ideas. It implies thinking beyond traditional boundaries or norms, fostering unique solutions to scientific and technological challenges.

Imagining Tomorrow's Science, a Methodology for Radical Imagination in Science and Technology from today. Radical Imagination to focus on encouraging highly creative, unconventional, or groundbreaking ideas. It implies thinking beyond traditional bo... Show more

Mario Birkholz ist Professor für Bioelektronik an der Technischen Universität Berlin und Leiter des Joint Lab Bioelectronics IHP/TUB, das vom IHP und der TU Berlin in 2012 gegründet wurde. Als ausgebildeter Physiker kam er 2004 ans IHP, dem Leibniz-Institut für innovative Mikroelektronik, wo er seitdem an den Anwendungen der Halbleiterphysik in Biotechnologie und Medizin arbeitet.
Seine Forschungsarbeiten fokussieren sich auf die Manipulation biologischer Zellen mit elektrischen Effekten sowie auf medizinische Sensoren und Implantate. Diese technischen Entwicklungen führten ihn auf die Frage der Privatheit von Gesundheitsdaten. Seine Aktivitäten betreffen deshalb zunehmend Fragen der nachhaltigen Digitalisierung und des Datenschutzes.

Mario Birkholz ist Professor für Bioelektronik an der Technischen Universität Berlin und Leiter des Joint Lab Bioelectronics IHP/TUB, das vom IHP und der TU Berlin in 2012 gegründet wurde. Als ausgebildeter Physiker kam er 2004 ans IHP, dem Leibniz-... Show more